A randomized controlled study of immunochemotherapy with OK-432 after curative surgery for gastric cancer.
The effect of adjuvant immunochemotherapy including OK-432 (Picibanil) on survival was assessed in patients who underwent curative resection of gastric cancer. Patients enrolled in this randomized controlled study were randomly assigned to group A or group B. Group A patients received 800 mg/d 5'-DFUR (Furtulon) for 2 years from 2 weeks after the operation. Group B patients received OK-432 plus 5'-DFUR by the same regimen as in group A. This study enrolled 288 patients, and 1 patient with malignant lymphoma was excluded. Among the remaining 287 patients, 143 and 144 were allocated to group A and group B, respectively, and their data were included in statistical analysis. The 5-year survival rates for groups A and B were 62.9% and 63.8%, respectively, showing no significant difference (P = 0.7996).
Sato
Yuji
Y
First Department of Surgery, School of Medicine, Hokkaido University, Sapporo, Japan. yuchan@med.hokudai.ac.jp
Kondo
Masao
M
Kohashi
Shigechika
S
Takahashi
Norihiko
N
Takahashi
Syusaku
S
Sinohara
Toshiki
T
Ono
Ken-Ichi
K
Matsuda
Miyuki
M
Ryoma
Yoshiki
Y
Shiroto
Hiroshi
H
Kondo
Yukihumi
Y
Uchino
Jun-Ichi
J
Saito
Kazuo
K
Todo
Satoru
S
D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D005260:Female; D005467:Floxuridine / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D010844:Picibanil / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality; D016019:Survival Analysis
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D005467:Floxuridine; D010844:Picibanil; C025034:doxifluridine